百洋医药：控股股东拟减持不超过3%

Group 1 - The controlling shareholder, Baiyang Pharmaceutical Group Co., Ltd., plans to reduce its stake by up to 15.7686 million shares, representing 3.00% of the total share capital, between August 12, 2025, and November 11, 2025 [1] - The reason for the reduction is due to the shareholder's funding needs, and the selling price will be determined based on market conditions [1] - Currently, Baiyang Group holds 369 million shares, accounting for 70.22% of the company's total share capital [1]